National Quality Measures Clearinghouse | Home

National Quality Measures Clearinghouse | Home

CHIPRQ PQMP QMETRIC Sickle Cell Disease Treatment Measures at NQMC

Measures developed and tested by the Quality Measurement, Evaluation, Testing, Review, and Implementation Consortium (Q-METRIC) at the University of Michigan, led by Gary Freed, MD, have now been approved and posted by the National Quality Measures Clearinghouse. All measures are available for public use.

Go to:  http://www.qualitymeasures.ahrq.gov/

The HHS Measure Inventory, a repository of measures separate from the NQMC, captures measures currently being used by the agencies of the U.S. Department of Health and Human Services for quality measurement, improvement, and reporting. Only some of the measures in the HHS Measure Inventory meet criteria for inclusion in the NQMC.

March 30, 2015

Measure Summaries

National Committee for Quality Assurance

-

Annual monitoring for patients on persistent medications: percentage of members 18 years of age and older who received at least 180 treatment days of ambulatory medication therapy for a select therapeutic agent during the measurement year and at least one therapeutic monitoring event for the therapeutic agent in the measurement year.  This updates a previously published measure summary.

-

Disease-modifying anti-rheumatic drug therapy for rheumatoid arthritis: percentage of members who were diagnosed with rheumatoid arthritis and who were dispensed at least one ambulatory prescription for a disease modifying anti-rheumatic drug (DMARD).  This updates a previously published measure summary.

-

Medication reconciliation post-discharge: percentage of discharges from January 1 to December 1 of the measurement year for members 66 years of age and older for whom medications were reconciled on or within 30 days of discharge.  This updates a previously published measure summary.

-

Osteoporosis management in women who had a fracture: percentage of women 67 to 85 years of age who suffered a fracture and who had either a bone mineral density (BMD) test or prescription for a drug to treat or prevent osteoporosis in the six months after the fracture.  This updates a previously published measure summary.

-

Potentially harmful drug-disease interactions in the elderly: percentage of Medicare members 65 years of age and older who have evidence of underlying disease, condition or health concern and who were dispensed an ambulatory prescription for a potentially harmful medication, concurrent with or after the diagnosis.  This updates a previously published measure summary.

-

Use of high-risk medications in the elderly: percentage of Medicare members 66 years of age and older who received at least one high-risk medication.  This updates a previously published measure summary.

-

Use of high-risk medications in the elderly: percentage of Medicare members 66 years of age and older who received at least two different high-risk medications.  This updates a previously published measure summary.

-

Use of imaging studies for low back pain: percentage of members with a primary diagnosis of low back pain who did not have an imaging study (plain x-ray, MRI, CT scan) within 28 days of the diagnosis.  This updates a previously published measure summary.